Fibroblast growth factor 4 (FGF-4) (FGF-4)

Fibroblast growth factor 4 (FGF-4) is a secreted protein that functions as a paracrine signaling molecule within the fibroblast growth factor family (UniProt P08620). It is essential for normal embryonic development, particularly in limb morphogenesis, tooth development, and the maintenance of pluripotent stem cells (NIH PMC11193144). In adults, FGF-4 contributes to physiological processes such as wound healing and angiogenesis by activating fibroblast growth factor receptors (FGFRs), primarily FGFR1 through FGFR4 (GeneCards FGF4). The binding of FGF-4 to its receptors requires heparin or heparan sulfate as a cofactor to induce receptor dimerization and subsequent activation of downstream cascades like the MAPK and PI3K pathways (MDPI Cancers 2019). Pathologically, FGF-4 is a potent oncogene; its gene is frequently amplified or overexpressed in various malignancies, including breast, gastric, and head and neck cancers, where it promotes tumor cell survival and metastasis (OncoKB FGF4). Therapeutic interventions targeting the FGF-4 signaling axis include the use of pan-FGFR inhibitors and selective FGFR4 inhibitors, with FGF-4 genomic alterations serving as key biomarkers for identifying patients likely to benefit from these targeted therapies (NIH PMC6359195).

Other names

FGF4HSTHST-1HSTF1HBGF-4Transforming protein KS3K-FGFKFGFHeparin secretory-transforming protein 1Kaposi sarcoma oncogeneHSTF-1KS3

Inhibition of fibroblast growth factor receptor (FGFR) tyrosine kinase activity or ligand sequestration, which prevents the activation of downstream signaling pathways such as RAS-MAPK, PI3K-AKT, and PLC-gamma initiated by FGF-4 binding.